On the stock market since 2021, it operates in the world of health and science. It has 91 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $33.0M a year. A small number, but proof the product has real buyers.
There is $103.0M in the vault; even if every debt were paid off, $85.1M would remain.
Over the last 12 months, company executives reported 25 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $44.6M against $33.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
On our five-subject report card, MXCT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MXCT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.